BIIB · Biogen Inc
Snapshot
50 fields · last close| Market Cap | $33.82B |
| P/E | 40.53 |
| Float | 147.4M |
| Beta | 0.10 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79.6 |
| Price | 229.18 |
| Change | +0.12% |
| Prev Close | 228.90 |
| Open | 230.34 |
| Day Low | 226.71 |
| Day High | 231.03 |
| Avg Vol | 1 |
| Avg $ Vol | $277.5M |
| 52W High | 238.24 |
| 52W Low | 138.00 |
| 52W Pos | 91.0% |
| From High | −3.80% |
| From Low | +66.07% |
| Max DD 1Y | — |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | — |
| SMA 50 | — |
| SMA 200 | — |
| RSI (14) | — |
| Vol 30D | — |
| Vol 90D | — |
| 1Y Range | 138–238 |
| Daily bars | — |
| Perf Week | — |
| Perf Month | — |
| Perf Quarter | — |
| Perf Half Y | — |
| Perf Year | — |
| Perf YTD | — |
| Prev Day | +0.12% |
| Clavix | B+ |
| Debt / Eq | 0.42 |
| Curr Ratio | 2.68 |
| Int Cover | 3.4× |
| FCF Margin | 20.7% |
| Rev Growth | +2.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 4 / 35 |
What BIIB does
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Clavix risk grade
regraded every trading dayBIIB grades B+, 79.6 of 100. Steadiest on Macro Resilience (73), most exposed on Price Stability (61, mixed). 4 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 4 of 35 in Biotechnology by Clavix score.
How rough the ride is
| BIIB | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.10 | 0.50 |
| Volatilityannualized | 5.0% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | — | — |
| Typical daily movemedian absolute daily change | — | — |
| Days beyond ±3%of the last 0 sessions | — | — |
Market sensitivity
| BIIB | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.10 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BIIB | |
|---|---|
| 1 week | — |
| 1 month | — |
| Year to date | — |
| 1 year | — |
Context for the rank, not itself a risk measure.
No scored coverage for BIIB in the recent pool.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| BIIB | |
|---|---|
| Revenue growthyear over year | +2.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $29.95B | 37.45 | 0.36 | Compare |
| RVMD | Revolution Medicines Inc | B- | $40.39B | — | 1.42 | Compare |
| UTHR | United Therapeutics Corp | B | $23.31B | 17.85 | 0.49 | Compare |
| INCY | Incyte Corp | B+ | $22.02B | 13.65 | 0.78 | Compare |
| INSM | Insmed Inc | C | $21.14B | — | 0.80 | Compare |
| NTRA | Natera Inc | B- | $57.03B | — | 1.53 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $77.54B | 17.87 | 0.13 | Compare |
| EXEL | Exelixis Inc | B+ | $14.75B | 17.09 | 0.44 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.